These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15478856)

  • 1. Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance.
    Kimmey MB
    Am J Med; 2004 Sep; 117 Suppl 5A():72S-78S. PubMed ID: 15478856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications.
    Peura DA
    Am J Med; 2004 Sep; 117 Suppl 5A():63S-71S. PubMed ID: 15478855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
    Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
    Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care.
    Martín Merino E; Johansson S; Nagy P; García Rodríguez LA
    Am J Cardiol; 2013 Oct; 112(8):1075-82. PubMed ID: 23831164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to reduce the GI risks of antiplatelet therapy.
    Scheiman JM
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S23-31. PubMed ID: 17710073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin.
    Hsu PI; Tsai TJ
    Curr Pharm Des; 2015; 21(35):5049-55. PubMed ID: 26369688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
    Laine L
    Rev Gastroenterol Disord; 2004; 4 Suppl 4():S33-41. PubMed ID: 15580145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment.
    Lanas A; Scheiman J
    Curr Med Res Opin; 2007 Jan; 23(1):163-73. PubMed ID: 17257477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The aspirin cardiovascular/gastrointestinal risk calculator--a tool to aid clinicians in practice.
    Lanas A; Polo-Tomás M; Casado-Arroyo R
    Aliment Pharmacol Ther; 2013 Apr; 37(7):738-48. PubMed ID: 23413984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events.
    Sylvester KW; Cheng JW; Mehra MR
    Vasc Health Risk Manag; 2013; 9():245-54. PubMed ID: 23696706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention.
    Lavie CJ; Howden CW; Scheiman J; Tursi J
    Curr Probl Cardiol; 2017 May; 42(5):146-164. PubMed ID: 28363584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin and omeprazole for secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.
    García-Rayado G; Sostres C; Lanas A
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):875-888. PubMed ID: 28463532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.
    Peura DA; Wilcox CM
    Postgrad Med; 2014 Jan; 126(1):87-96. PubMed ID: 24393755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
    Vaduganathan M; Bhatt DL; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Cannon CP;
    J Am Coll Cardiol; 2016 Apr; 67(14):1661-71. PubMed ID: 27012778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reinitiating aspirin therapy for primary prevention of cardiovascular events in a patient post-aspirin-induced upper gastrointestinal bleed: a case report and review of literature.
    Adly G; Plakogiannis R
    Ann Pharmacother; 2013 Feb; 47(2):e8. PubMed ID: 23386069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
    Chan FK; Graham DY
    Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis.
    Lotrionte M; Biasucci LM; Peruzzi M; Frati G; Giordano A; Biondi-Zoccai G
    Prog Cardiovasc Dis; 2016; 58(5):495-504. PubMed ID: 26851562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The David Y. Graham lecture: use of nonsteroidal antiinflammatory drugs in a COX-2 restricted environment.
    Chan FK
    Am J Gastroenterol; 2008 Jan; 103(1):221-7. PubMed ID: 17900323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease.
    Sharma T; Bliden K; Chaudhary R; Tantry U; Gurbel PA
    Expert Opin Pharmacother; 2017 Jan; 18(1):123-131. PubMed ID: 27937054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.